Kymera Therapeutics (KYMR) Scheduled to Post Earnings on Thursday

Kymera Therapeutics (NASDAQ:KYMR - Get Free Report) will issue its quarterly earnings data before the market opens on Thursday, May 2nd. Analysts expect the company to announce earnings of ($0.73) per share for the quarter. Parties interested in registering for the company's conference call can do so using this link.

Kymera Therapeutics (NASDAQ:KYMR - Get Free Report) last issued its earnings results on Thursday, February 22nd. The company reported ($0.25) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.44) by $0.19. Kymera Therapeutics had a negative return on equity of 34.83% and a negative net margin of 187.00%. The firm had revenue of $47.90 million for the quarter, compared to analysts' expectations of $41.94 million. During the same period in the previous year, the firm posted ($0.60) earnings per share. The business's revenue was up 197.5% compared to the same quarter last year. On average, analysts expect Kymera Therapeutics to post $-3 EPS for the current fiscal year and $-3 EPS for the next fiscal year.

Kymera Therapeutics Price Performance

Shares of KYMR stock traded up $0.02 during trading hours on Friday, hitting $33.37. The stock had a trading volume of 452,363 shares, compared to its average volume of 730,111. Kymera Therapeutics has a one year low of $9.60 and a one year high of $45.31. The stock's 50-day moving average price is $38.91 and its two-hundred day moving average price is $28.54. The stock has a market capitalization of $2.04 billion, a price-to-earnings ratio of -13.24 and a beta of 2.27.

Analyst Upgrades and Downgrades

Several research analysts recently commented on the company. Oppenheimer assumed coverage on Kymera Therapeutics in a research report on Monday. They issued an "outperform" rating and a $53.00 price target for the company. Bank of America lowered Kymera Therapeutics from a "buy" rating to a "neutral" rating and dropped their price target for the stock from $45.00 to $30.00 in a research report on Wednesday, January 3rd. Truist Financial lifted their price target on Kymera Therapeutics from $41.00 to $54.00 and gave the stock a "buy" rating in a research report on Friday, March 1st. JPMorgan Chase & Co. lifted their price target on Kymera Therapeutics from $34.00 to $47.00 and gave the stock an "overweight" rating in a research report on Friday, February 23rd. Finally, Wolfe Research assumed coverage on Kymera Therapeutics in a research report on Thursday, February 15th. They set a "peer perform" rating for the company. Six equities research analysts have rated the stock with a hold rating and seven have assigned a buy rating to the stock. According to data from MarketBeat, the company has an average rating of "Moderate Buy" and a consensus price target of $41.20.

Insider Activity at Kymera Therapeutics

In related news, Director Bruce Booth sold 51,184 shares of the business's stock in a transaction that occurred on Monday, March 11th. The stock was sold at an average price of $42.85, for a total value of $2,193,234.40. Following the completion of the sale, the director now owns 881,266 shares in the company, valued at $37,762,248.10. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. In related news, Director Bruce Booth sold 51,184 shares of the business's stock in a transaction that occurred on Monday, March 11th. The stock was sold at an average price of $42.85, for a total value of $2,193,234.40. Following the completion of the sale, the director now owns 881,266 shares in the company, valued at $37,762,248.10. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, major shareholder Venture Fund X. L.P. Atlas sold 42,302 shares of the business's stock in a transaction that occurred on Monday, March 11th. The stock was sold at an average price of $42.85, for a total transaction of $1,812,640.70. Following the completion of the transaction, the insider now directly owns 4,925,812 shares of the company's stock, valued at approximately $211,071,044.20. The disclosure for this sale can be found here. Over the last quarter, insiders sold 474,051 shares of company stock worth $19,624,211. Company insiders own 16.67% of the company's stock.

About Kymera Therapeutics

Kymera Therapeutics, Inc, a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors.